THERAPEUTIC GOODS ADMINISTRATION (TGA) Find out more ». COVID-19: Information on medicines and medical devices. All information and updates relating to COVID-19 and therapeutic goods in Australia. Find out more ». GMP Forum 2021 - Registrations now open. The TGA is hosting the third GMP forum virtually, held on 12-14 May 2021. Find out more ». Nicotine

e-cigarettes.

COVID-19 VACCINE WEEKLY SAFETY REPORT COVID-19 vaccine weekly safety report - 06-05-2021. The Therapeutic Goods Administration (TGA) has been closely monitoring suspected side effects (also known as adverse events) from the use of COVID-19 vaccines since the national roll-out began on 22 February 2021. Importantly, adverse events reported to the TGA are often not caused

by the

AUSTRALIA'S COVID-19 VACCINE SAFETY MONITORING SYSTEMSEE MORE ON

TGA.GOV.AU

COVID-19 VACCINE WEEKLY SAFETY REPORT They include headache, muscle and joint pain, fever and injection site reactions. The most common reactions reported for the AstraZeneca COVID-19 vaccine in the week of 17-23 May 2021 were headache, muscle pain, fever, chills and fatigue. The most common reactions reported for the Comirnaty (Pfizer) COVID-19 vaccine in the week of 17-23 May AUSTRALIAN REGISTER OF THERAPEUTIC GOODS AANs and Proprietary Ingredients. 1800 020 653. TGAnames@tga.gov.au. (link sends e-mail) TGA eBusiness Services Help Desk. 1800 010 624. ebs@tga.gov.au. (link sends e-mail) Requests for searches and reports

from the ARTG.

SEARCHING THE AUSTRALIAN REGISTER OF THERAPEUTIC GOODSSEE MORE ON

TGA.GOV.AU

SPECIFIC CLOTTING CONDITION REPORTED AFTER COVID-19 Some rare cases of thrombosis associated with thrombocytopenia have been reported overseas following the administration of COVID-19 Vaccine AstraZeneca. TGA EBUSINESS SERVICES The Electronic Business Services (eBS) page of Therapeutic Goods Administration (TGA) part of the Commonwealth Department of Health and Ageing. TGA is Australia's regulatory agency for medical drugs and devices. TGA eBS provides facilities for the online lodgement of data packages in support of applications for entry of products onto the Australian Register of Therapeutic Goods (ARTG) and THE POISONS STANDARD (THE SUSMP) The Poisons Standard is a Legislative Instrument for the purposes of the Legislative Instruments Act 2003.The Poisons Standard consists of decisions regarding the classification of medicines and poisons into Schedules for inclusion in the relevant legislation of the States and

Territories.

THERAPEUTIC GOODS ADMINISTRATION (TGA) Find out more ». COVID-19: Information on medicines and medical devices. All information and updates relating to COVID-19 and therapeutic goods in Australia. Find out more ». GMP Forum 2021 - Registrations now open. The TGA is hosting the third GMP forum virtually, held on 12-14 May 2021. Find out more ». Nicotine

e-cigarettes.

COVID-19 VACCINE WEEKLY SAFETY REPORT COVID-19 vaccine weekly safety report - 06-05-2021. The Therapeutic Goods Administration (TGA) has been closely monitoring suspected side effects (also known as adverse events) from the use of COVID-19 vaccines since the national roll-out began on 22 February 2021. Importantly, adverse events reported to the TGA are often not caused

by the

AUSTRALIA'S COVID-19 VACCINE SAFETY MONITORING SYSTEMSEE MORE ON

TGA.GOV.AU

COVID-19 VACCINE WEEKLY SAFETY REPORT They include headache, muscle and joint pain, fever and injection site reactions. The most common reactions reported for the AstraZeneca COVID-19 vaccine in the week of 17-23 May 2021 were headache, muscle pain, fever, chills and fatigue. The most common reactions reported for the Comirnaty (Pfizer) COVID-19 vaccine in the week of 17-23 May AUSTRALIAN REGISTER OF THERAPEUTIC GOODS AANs and Proprietary Ingredients. 1800 020 653. TGAnames@tga.gov.au. (link sends e-mail) TGA eBusiness Services Help Desk. 1800 010 624. ebs@tga.gov.au. (link sends e-mail) Requests for searches and reports

from the ARTG.

SEARCHING THE AUSTRALIAN REGISTER OF THERAPEUTIC GOODSSEE MORE ON

TGA.GOV.AU

SPECIFIC CLOTTING CONDITION REPORTED AFTER COVID-19 Some rare cases of thrombosis associated with thrombocytopenia have been reported overseas following the administration of COVID-19 Vaccine AstraZeneca. TGA EBUSINESS SERVICES The Electronic Business Services (eBS) page of Therapeutic Goods Administration (TGA) part of the Commonwealth Department of Health and Ageing. TGA is Australia's regulatory agency for medical drugs and devices. TGA eBS provides facilities for the online lodgement of data packages in support of applications for entry of products onto the Australian Register of Therapeutic Goods (ARTG) and THE POISONS STANDARD (THE SUSMP) The Poisons Standard is a Legislative Instrument for the purposes of the Legislative Instruments Act 2003.The Poisons Standard consists of decisions regarding the classification of medicines and poisons into Schedules for inclusion in the relevant legislation of the States and

Territories.

COVID-19 VACCINE WEEKLY SAFETY REPORT The most frequently reported suspected side effects associated with Comirnaty (Pfizer) and AstraZeneca COVID-19 vaccines continue to be events that were seen in the clinical trials, and are commonly experienced with vaccines generally.; Seven additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia syndrome (TTS) likely to be linked COMMUNICATING ABOUT COVID-19 VACCINES Offering rewards. Any party can offer valuable consideration (cash or other rewards) to people who have been fully vaccinated under the Government's national COVID-19 vaccination program, subject to the following conditions:. the offer can only be made to people who have been fully vaccinated, which for the current approved COVID-19 vaccines, means two vaccinations. COVID-19 VACCINE WEEKLY SAFETY REPORT The most common reactions reported for the Comirnaty (Pfizer) COVID-19 vaccine in the week of 10-16 May 2021 were headache, muscle pain, injection site reactions, fever and lethargy. This week we report on fatigue as a side effect as it has been frequently reported with both

vaccines.

COVID-19 VACCINE WEEKLY SAFETY REPORT The Therapeutic Goods Administration (TGA) has been closely monitoring suspected side effects (also known as adverse events) from the use of COVID-19 vaccines since the national roll-out began on 22 February 2021. Importantly, adverse events

LISTED MEDICINES

Listed medicines are usually considered to be relatively benign, so the regulations allow for sponsors to 'self assess' their products in some situations. The majority of listed medicines are self-selected by consumers and used for self-treatment. SEARCHING THE AUSTRALIAN REGISTER OF THERAPEUTIC GOODS On this page: About the ARTG | Using the ARTG search function | ARTG dates About the ARTG. The publicly accessible version of the Australian Register of Therapeutic Goods (ARTG) is the reference database of the Therapeutic Goods Administration (TGA). It provides information on therapeutic goods that can be supplied in Australia. SPECIFIC CLOTTING CONDITION REPORTED AFTER COVID-19 Some rare cases of thrombosis associated with thrombocytopenia have been reported overseas following the administration of COVID-19 Vaccine AstraZeneca. MISLEADING RADIO MESSAGES ABOUT COVID-19 VACCINE SAFETY The Therapeutic Goods Administration is seriously concerned about misleading information, authorised by Mr Clive Palmer that has recently been broadcast on radio stations in the Grant Broadcasters Radio network and which provides an incorrect picture of the safety of

COVID-19 vaccines.

TGA EBUSINESS SERVICES The Electronic Business Services (eBS) page of Therapeutic Goods Administration (TGA) part of the Commonwealth Department of Health and Ageing. TGA is Australia's regulatory agency for medical drugs and devices. TGA eBS provides facilities for the online lodgement of data packages in support of applications for entry of products onto the Australian Register of Therapeutic Goods (ARTG) and ZEBINIX | THERAPEUTIC GOODS ADMINISTRATION (TGA) The Australian Prescription Medicine Decision Summary provides a short overview of the TGA's evaluation process leading to the registration of a new prescription medicine on the Australian Register of Therapeutic Goods (ARTG).. More in-depth information about the evaluation will be available in the Australian Public Assessment Report (AusPAR) for a particular prescription medicine, which can THERAPEUTIC GOODS ADMINISTRATION (TGA) Australian Government Department of Health. The following article provides information for women who have breast implants or are considering getting them. COVID-19 VACCINE WEEKLY SAFETY REPORT The most frequently reported suspected side effects associated with Comirnaty (Pfizer) and AstraZeneca COVID-19 vaccines continue to be events that were seen in the clinical trials, and are commonly experienced with vaccines generally.. Nine additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia syndrome (TTS) likely to be linked AUSTRALIA'S COVID-19 VACCINE SAFETY MONITORING SYSTEMSEE MORE ON

TGA.GOV.AU

COVID-19 VACCINE WEEKLY SAFETY REPORT The Therapeutic Goods Administration (TGA) has been closely monitoring suspected side effects (also known as adverse events) from the use of

COVID-19 vaccines

CORONAVIRUS (COVID-19): INFORMATION ON MEDICINES AND The TGA is publishing the latest information about medicines and medical devices as it relates to COVID-19 on this page. Please read the information below before contacting the TGA to see if your question is already answered. COVID-19 VACCINE WEEKLY SAFETY REPORT The most frequently reported suspected side effects associated with Comirnaty (Pfizer) and AstraZeneca COVID-19 vaccines continue to be events that were seen in the clinical trials, and are commonly experienced with vaccines generally.. Six additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia syndrome (TTS) likely to be linked THERAPEUTIC GOODS ADMINISTRATION (TGA) Australian Government Department of Health. The following article provides information for women who have breast implants or are considering getting them. COVID-19 VACCINE WEEKLY SAFETY REPORT The most frequently reported suspected side effects associated with Comirnaty (Pfizer) and AstraZeneca COVID-19 vaccines continue to be events that were seen in the clinical trials, and are commonly experienced with vaccines generally.. Nine additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia syndrome (TTS) likely to be linked AUSTRALIA'S COVID-19 VACCINE SAFETY MONITORING SYSTEMSEE MORE ON

TGA.GOV.AU

COVID-19 VACCINE WEEKLY SAFETY REPORT The Therapeutic Goods Administration (TGA) has been closely monitoring suspected side effects (also known as adverse events) from the use of

COVID-19 vaccines

CORONAVIRUS (COVID-19): INFORMATION ON MEDICINES AND The TGA is publishing the latest information about medicines and medical devices as it relates to COVID-19 on this page. Please read the information below before contacting the TGA to see if your question is already answered. COVID-19 VACCINE WEEKLY SAFETY REPORT The most frequently reported suspected side effects associated with Comirnaty (Pfizer) and AstraZeneca COVID-19 vaccines continue to be events that were seen in the clinical trials, and are commonly experienced with vaccines generally.. Six additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia syndrome (TTS) likely to be linked CORONAVIRUS (COVID-19): INFORMATION ON MEDICINES AND The TGA is publishing the latest information about medicines and medical devices as it relates to COVID-19 on this page. Please read the information below before contacting the TGA to see if your question is already answered. COMMUNICATING ABOUT COVID-19 VACCINES Offering rewards. Any party can offer valuable consideration (cash or other rewards) to people who have been fully vaccinated under the Government's national COVID-19 vaccination program, subject to the following conditions:. the offer can only be made to people who have been fully vaccinated, which for the current approved COVID-19 vaccines, means two vaccinations. COVID-19 VACCINE WEEKLY SAFETY REPORT The most frequently reported suspected side effects associated with Comirnaty (Pfizer) and AstraZeneca COVID-19 vaccines continue to be events that were seen in the clinical trials, and are commonly experienced with vaccines generally.; Seven additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia syndrome (TTS) likely to be linked AUSTRALIAN REGISTER OF THERAPEUTIC GOODS Query Phone number Email; Medical devices: 1800 141 144: devices@tga.gov.au: Medicines: 1800 020 653: info@tga.gov.au: Biologicals: 1800 678 799: bloodandtissues@tga MISLEADING RADIO MESSAGES ABOUT COVID-19 VACCINE SAFETY The Therapeutic Goods Administration is seriously concerned about misleading information, authorised by Mr Clive Palmer that has recently been broadcast on radio stations in the Grant Broadcasters Radio network and which provides an incorrect picture of the safety of

COVID-19 vaccines.

SPECIFIC CLOTTING CONDITION REPORTED AFTER COVID-19 Some rare cases of thrombosis associated with thrombocytopenia have been reported overseas following the administration of COVID-19 Vaccine AstraZeneca. TGA EBUSINESS SERVICES The Electronic Business Services (eBS) page of Therapeutic Goods Administration (TGA) part of the Commonwealth Department of Health and Ageing. TGA is Australia's regulatory agency for medical drugs and devices. TGA eBS provides facilities for the online lodgement of data packages in support of applications for entry of products onto the Australian Register of Therapeutic Goods (ARTG) and

MEDICINE SHORTAGES

A medicine shortage occurs when there is unlikely to be enough of a medicine in Australia for the people who need to take it. Suppliers must report shortages of prescription medicines and a small number of over-the-counter medicines to the TGA. ZEBINIX | THERAPEUTIC GOODS ADMINISTRATION (TGA) The Australian Prescription Medicine Decision Summary provides a short overview of the TGA's evaluation process leading to the registration of a new prescription medicine on the Australian Register of Therapeutic Goods (ARTG).. More in-depth information about the evaluation will be available in the Australian Public Assessment Report (AusPAR) for a particular prescription medicine, which can

SIGN IN

Sign in with your organizational account Sign in THERAPEUTIC GOODS ADMINISTRATION (TGA) Find out more ». COVID-19: Information on medicines and medical devices. All information and updates relating to COVID-19 and therapeutic goods in Australia. Find out more ». GMP Forum 2021 - Registrations now open. The TGA is hosting the third GMP forum virtually, held on 12-14 May 2021. Find out more ». Nicotine

e-cigarettes.

COVID-19 VACCINE WEEKLY SAFETY REPORT COVID-19 vaccine weekly safety report - 06-05-2021. The Therapeutic Goods Administration (TGA) has been closely monitoring suspected side effects (also known as adverse events) from the use of COVID-19 vaccines since the national roll-out began on 22 February 2021. Importantly, adverse events reported to the TGA are often not caused

by the

AUSTRALIA'S COVID-19 VACCINE SAFETY MONITORING SYSTEMSEE MORE ON

TGA.GOV.AU

COVID-19 VACCINE WEEKLY SAFETY REPORT They include headache, muscle and joint pain, fever and injection site reactions. The most common reactions reported for the AstraZeneca COVID-19 vaccine in the week of 17-23 May 2021 were headache, muscle pain, fever, chills and fatigue. The most common reactions reported for the Comirnaty (Pfizer) COVID-19 vaccine in the week of 17-23 May AUSTRALIAN REGISTER OF THERAPEUTIC GOODS AANs and Proprietary Ingredients. 1800 020 653. TGAnames@tga.gov.au. (link sends e-mail) TGA eBusiness Services Help Desk. 1800 010 624. ebs@tga.gov.au. (link sends e-mail) Requests for searches and reports

from the ARTG.

SPECIFIC CLOTTING CONDITION REPORTED AFTER COVID-19 Some rare cases of thrombosis associated with thrombocytopenia have been reported overseas following the administration of COVID-19 Vaccine AstraZeneca. ESSENTIAL PRINCIPLES CHECKLIST (MEDICAL DEVICES Essential principles checklist (medical devices) 22 March 2021. It is the manufacturer's responsibility to demonstrate compliance with the essential principles for their medical devices. How to access a pdf or Word document. Medical devices essential principles checklist (pdf,230kb) Medical devices essential principles checklist

(docx,223kb)

THE POISONS STANDARD (THE SUSMP) The Poisons Standard is a Legislative Instrument for the purposes of the Legislative Instruments Act 2003.The Poisons Standard consists of decisions regarding the classification of medicines and poisons into Schedules for inclusion in the relevant legislation of the States and

Territories.

VARIATIONS TO PRESCRIPTION MEDICINES Guidance Process. Variations to prescription medicines - excluding variations requiring the evaluation of clinical or bioequivalence data: Process guidance THERAPEUTIC GOODS ADMINISTRATION (TGA) Find out more ». COVID-19: Information on medicines and medical devices. All information and updates relating to COVID-19 and therapeutic goods in Australia. Find out more ». GMP Forum 2021 - Registrations now open. The TGA is hosting the third GMP forum virtually, held on 12-14 May 2021. Find out more ». Nicotine

e-cigarettes.

COVID-19 VACCINE WEEKLY SAFETY REPORT COVID-19 vaccine weekly safety report - 06-05-2021. The Therapeutic Goods Administration (TGA) has been closely monitoring suspected side effects (also known as adverse events) from the use of COVID-19 vaccines since the national roll-out began on 22 February 2021. Importantly, adverse events reported to the TGA are often not caused

by the

AUSTRALIA'S COVID-19 VACCINE SAFETY MONITORING SYSTEMSEE MORE ON

TGA.GOV.AU

COVID-19 VACCINE WEEKLY SAFETY REPORT They include headache, muscle and joint pain, fever and injection site reactions. The most common reactions reported for the AstraZeneca COVID-19 vaccine in the week of 17-23 May 2021 were headache, muscle pain, fever, chills and fatigue. The most common reactions reported for the Comirnaty (Pfizer) COVID-19 vaccine in the week of 17-23 May AUSTRALIAN REGISTER OF THERAPEUTIC GOODS AANs and Proprietary Ingredients. 1800 020 653. TGAnames@tga.gov.au. (link sends e-mail) TGA eBusiness Services Help Desk. 1800 010 624. ebs@tga.gov.au. (link sends e-mail) Requests for searches and reports

from the ARTG.

SPECIFIC CLOTTING CONDITION REPORTED AFTER COVID-19 Some rare cases of thrombosis associated with thrombocytopenia have been reported overseas following the administration of COVID-19 Vaccine AstraZeneca. ESSENTIAL PRINCIPLES CHECKLIST (MEDICAL DEVICES Essential principles checklist (medical devices) 22 March 2021. It is the manufacturer's responsibility to demonstrate compliance with the essential principles for their medical devices. How to access a pdf or Word document. Medical devices essential principles checklist (pdf,230kb) Medical devices essential principles checklist

(docx,223kb)

THE POISONS STANDARD (THE SUSMP) The Poisons Standard is a Legislative Instrument for the purposes of the Legislative Instruments Act 2003.The Poisons Standard consists of decisions regarding the classification of medicines and poisons into Schedules for inclusion in the relevant legislation of the States and

Territories.

VARIATIONS TO PRESCRIPTION MEDICINES Guidance Process. Variations to prescription medicines - excluding variations requiring the evaluation of clinical or bioequivalence data: Process guidance COMMUNICATING ABOUT COVID-19 VACCINES Offering rewards. Any party can offer valuable consideration (cash or other rewards) to people who have been fully vaccinated under the Government's national COVID-19 vaccination program, subject to the following conditions:. the offer can only be made to people who have been fully vaccinated, which for the current approved COVID-19 vaccines, means two vaccinations. COVID-19 VACCINE WEEKLY SAFETY REPORT The most common reactions reported for the Comirnaty (Pfizer) COVID-19 vaccine in the week of 10-16 May 2021 were headache, muscle pain, injection site reactions, fever and lethargy. This week we report on fatigue as a side effect as it has been frequently reported with both

vaccines.

COVID-19 VACCINE WEEKLY SAFETY REPORT The most frequently reported suspected side effects associated with Comirnaty (Pfizer) and AstraZeneca COVID-19 vaccines continue to be events that were seen in the clinical trials, and are commonly experienced with vaccines generally.; Eight additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia syndrome (TTS) likely to be linked MISLEADING RADIO MESSAGES ABOUT COVID-19 VACCINE SAFETY The Therapeutic Goods Administration is seriously concerned about misleading information, authorised by Mr Clive Palmer that has recently been broadcast on radio stations in the Grant Broadcasters Radio network and which provides an incorrect picture of the safety of

COVID-19 vaccines.

SPECIFIC CLOTTING CONDITION REPORTED AFTER COVID-19 Some rare cases of thrombosis associated with thrombocytopenia have been reported overseas following the administration of COVID-19 Vaccine AstraZeneca. SEARCHING THE AUSTRALIAN REGISTER OF THERAPEUTIC GOODS On this page: About the ARTG | Using the ARTG search function | ARTG dates About the ARTG. The publicly accessible version of the Australian Register of Therapeutic Goods (ARTG) is the reference database of the Therapeutic Goods Administration (TGA). It provides information on therapeutic goods that can be supplied in Australia. NEW REGULATORY ARRANGEMENTS SUPPORT BUSINESSES AND HEALTH The TGA has implemented arrangements to facilitate the communication of information about approved COVID-19 vaccines. TGA EBUSINESS SERVICES The Electronic Business Services (eBS) page of Therapeutic Goods Administration (TGA) part of the Commonwealth Department of Health and Ageing. TGA is Australia's regulatory agency for medical drugs and devices. TGA eBS provides facilities for the online lodgement of data packages in support of applications for entry of products onto the Australian Register of Therapeutic Goods (ARTG) and RELEASE FOR SUPPLY OF MEDICINES This guidance is for TGA licensed or certified manufacturers and Australian sponsors of a medicine manufactured under the PIC/S Guide to GMP for medicinal products (PIC/S Guide to GMP). This guidance outlines: our interpretation of release for supply (RFS) of medicines in Australia. your responsibilities related to RFS of medicines. EVALUATION PLAN ESTIMATORS The evaluation plan estimators can be used to approximate the dates of the milestones in the prescription medicine registration process Skip to Content Skip to Main Navigation Skip to Search CONTACT TGA: info@tga.gov.au(link sends e-mail) | 1800 020 653

| More contact info

Translate | Subscribe THERAPEUTIC GOODS ADMINISTRATION (TGA) Australian Government Department of Health

MAIN MENU

* Home

* Safety information * Report a problem or side effect * Reporting adverse events involving medicines, vaccines or medical

devices

* Report an issue with packaging or storage of a medicine * AEMS guidance for health professionals * AEMS guidance for sponsors * Help us promote adverse event reporting: promotional resources kit

* Alerts

* Current year alerts

* All alerts

* Recalls

* About Australian recall actions * Recall actions database * Uniform recall procedure * Prescription opioids * Medicine shortages * Early warning system * Monitoring communications * About the Early Warning System * Early Warning System: consumer questions and answers * Early Warning System: health professional questions and answers * Black Triangle Scheme * Black Triangle Scheme: Information for sponsors * Safety information & education

* Medicines safety

* Medical devices safety * Database of Adverse Event Notifications (DAEN)

* COVID-19 vaccines

* COVID-19 vaccine approval process * Provisional registrations * COVID-19 vaccine safety monitoring and reporting

* News and updates

* COVID-19 vaccine advertising and import compliance * Information for consumers and health professionals * Information for sponsors (industry) * International collaboration

* Consumers

* Report a problem or side effect * Reporting adverse events involving medicines, vaccines or medical

devices

* Travelling with medicines and medical devices

* Leaving Australia

* Entering Australia * Helpful links for travellers * Buying medicines and medical devices online * Counterfeit medicines and devices

* Can I import it?

* Personal importation scheme * Medicinal cannabis: importation and the traveller's exemption

* Medicines

* How we regulate medicines * Prescription medicines * Complementary medicines * Over-the-counter (OTC) medicines

* Vaccines

* What's on my medicine label? * Accessing medicines during a medicines shortage * What ingredients are in my medicine?

* Medical devices

* Medical devices overview * Transvaginal (urogynaecological) surgical mesh hub * Breast implant hub * Cosmetic injections * Medical device cyber security

* Advertising hub

* Consumer information & education * Safety information for consumers * Medicines & medical devices

* Community Q&A

* MedSearch | Medicine information search app * Other web resources for consumers * Medicinal cannabis products * Health professionals * Report a problem or side effect * Reporting adverse events involving medicines, vaccines or medical

devices

* Accessing unapproved products * Special access scheme * Authorised prescribers

* Clinical trials

* Personal importation scheme * Medicine shortages: Information for Health Professionals * Accessing medicines during a medicine shortage * Medicinal cannabis * Nicotine e-cigarettes

* Advertising

* Medicines

* Labelling changes: information for health professionals * Registration of medicines for the medical termination of early

pregnancy

* Product Information * Prescribing medicines in pregnancy database * Medicine Shortages Information Initiative * Fast track approval pathways for prescription medicines

* Medical devices

* Breast implant associated-anaplastic large cell lymphoma (BIA-ALCL) * Breast implant hub * Changes to labelling and regulation of hard surface disinfectants (commencing 1 April 2019) * Information for medical practitioners on pending up-classification of surgical mesh devices * Importing & supplying medical devices * Advice about medical devices for health professionals

* Biologicals

* Regulation of stem cell treatments: information for practitioners * Safety information * Medicines Safety Update * Medical Devices Safety Update * Australian Adverse Drug Reactions Bulletin * Medical device incident reporting & investigation scheme (IRIS)

articles

* Implanting medical devices

* Other resources

* Health professional information & education * Health professional educational materials

* Industry

* SME Assist

* Basics of therapeutic goods regulation * SME Assist workshops and events * Educational videos * Overview of applying for market authorisation * Understanding ingredient requirements * Overview of medical devices and IVD regulation * Researcher considerations * Interactive decision tools * Useful resources for business and researchers

* Case studies

* SME guidance material

* Regulation basics

* How therapeutic goods are regulated in Australia * Australian Register of Therapeutic Goods * Industry educational materials * Legislation & legislative instruments

* Advertising hub

* Labelling & packaging * Ingredients in therapeutic goods * Exporting therapeutic goods * Importing therapeutic goods

* Clinical trials

* Cosmetics

* International scientific guidelines * Safety information for industry * Medicine shortages * Advertising therapeutic goods

* Getting started

* Complying with advertising requirements * Learning resources * Enforcement and outcomes

* News and reports

* Consultation and independent reviews * Prescription medicines * Australian Regulatory Guidelines for Prescription Medicines * Prescription medicines regulation basics * Standards and guidelines * Forms for prescription medicine sponsors * Regulatory decisions and notices * Over-the-counter medicines * OTC medicines regulation basics * Standards, guidelines and publications * Forms for OTC medicine sponsors * Regulatory decisions and notices * Complementary medicines * Complementary medicine regulation basics * Standards, guidelines and publications * Forms for complementary medicine sponsors * Complementary medicines reforms * Regulatory decisions and notices

* Sunscreens

* Sunscreens regulation basics * Standards, guidelines and publications

* Sunscreen reforms

* Medical devices & IVDs * Face masks and COVID-19 * Medical devices regulation basics * IVD medical devices regulation basics * Standards, guidelines and publications * Forms for medical device & IVD sponsors * Medical devices reforms * Regulatory decisions and notices

* Biologicals

* Australian Regulatory Guidelines for Biologicals * Regulatory framework for biologicals * Biological standards * Forms for the biologicals industry * Regulatory decisions and notices * Blood and blood components * Regulation of blood * Regulation of platelet-rich plasma (PRP), platelet-rich fibrin (PRF) and conditioned serum * Forms for the blood and blood components industry * Other therapeutic goods * Disinfectants, sterilants and sanitary products * Tampons & menstrual cups * Manufacturing therapeutic goods * Manufacturing basics * Manufacturing medicines * Manufacturing medical devices & IVDs * Manufacturing biologicals * Manufacturing blood and blood components * Manufacturing inspections * Forms for manufacturers * Notices for manufacturers * Notices about GMP clearance * Guidance on the management of GMP compliance signals * Scheduling of medicines & poisons

* Scheduling basics

* Scheduling committees meeting dates and decisions timeframes * The Poisons Standard (the SUSMP) * Public notices about scheduling * State/Territory scheduling information

* About the TGA

* TGA basics

* Who we are & what we do * What the TGA doesn't do

* Structure

* TGA plans & reports

* TGA reforms

* Publications

* Forms

* Freedom of information * Acronyms & glossary

* TGA Internet site

* Social media

* Contact the TGA

* How can we help?

* TGA customer service standards * Report a perceived breach or questionable practices * Website feedback or error reporting * Translate this website * Educational materials

* For consumers

* For health professionals

* For industry

* For university students * Education priorities 2018-19 * Compliance and enforcement hub * Compliance management * Compliance actions and outcomes * News and information

* Report a breach

* Regulatory decisions & notices * Consent to import, supply or export goods that do not comply with

standards

* Cancellation requested by the sponsor - regulatory actions * Failure to pay annual charges - regulatory actions * TGA laboratory testing results * AUST numbers on medicine labels * S19A approval notices

* Committees

* TGA statutory advisory committees

* Other committees

* Employment & job vacancies * Working for the TGA * Recruitment information * Living in Canberra

* Fees and payments

* Schedule of fees and charges

* Payment options

* Information & notices about TGA fees & payments * Cost recovery implementation statements * Forms (fees and payments) * Annual Charge Exemption (ACE) scheme * TGA Business Services * TGA Business services: getting started with the TGA * TGA Business services - how to use the site * TGA Business Services forms

* International

* International activities * International cooperation * Use of international assessments * TGA international engagement strategy * Links to international agencies & organisations * TGA Internet site archive * Archived behind the news articles * Archived committee information * Archived consultations & reviews * Archived media releases * Archived newsletters and articles * Archived presentations * Archived regulatory decisions & notices * Archived TGA publications

* News room

* News & public notices * Latest news & updates * Media releases & statements

* Behind the news

* Newsletters & articles * Subscribe to updates

* TGA tenders

* TGA laboratory testing reports * Consultations & reviews * Open consultations & reviews * Closed consultations & reviews * About consultations * Consultation forecast * Medicines and Medical Devices Regulation Review * Events, training & presentations

* Events & training

* Presentations

* Blog

* TGA topics

*

COVID-19 VACCINES

Information and updates on the regulatory processes for approving

COVID-19 vaccines

Find out more »

*

COVID-19: INFORMATION ON MEDICINES AND MEDICAL DEVICES All information and updates relating to COVID-19 and therapeutic goods

in Australia

Find out more »

*

DETERMINATION OF AUSTRALIAN CONFORMITY ASSESSMENT BODIES Australian corporations can apply to become an Australian Conformity Assessment Body from 1 July 2021.

Find out more »

*

NICOTINE E-CIGARETTES The law regulating imports of nicotine e-cigarettes is changing from 1

October 2021.

Find out more »

*

INFORMATION FOR WOMEN WITH BREAST IMPLANTS The following article provides information for women who have breast implants or are considering getting them.

Find out more »

* 1

* 2

* 3

* 4

* 5

Pause

CONSUMERS

__

Personal importation

__

For travellers

__

Buying online

HEALTH PROFESSIONALS

__

Reporting problems

__

Unapproved products

__

Special access scheme

INDUSTRY

__

SME Assist

__

Regulation basics

__

Scheduling basics

RECALLS AND SUSPENSIONS OSPOLOT (SULTHIAME) TABLETS 200 MG

3 June 2021

Product Defect Alert –child-resistant caps may not function

correctly

HYDRALYTE STRAWBERRY KIWI EFFERVESCENT ELECTROLYTE TABLETS

21 May 2021

Recall due to unacceptable risk in pregnancy LIFEPAK CR2 DEFIBRILLATOR

6 April 2021

Product defect correction - lid magnet may dislodge and cause early

battery depletion

VARIOUS MEDICINES CONTAINING ARTEMISIA ANNUA AND ARTEMISIA ABSINTHIUM

23 March 2021

Recall of various medicines containing Artemisia annua and Artemisia absinthium - updated recalled medicines More safety information »

SAFETY INFORMATION

COVID-19 VACCINE WEEKLY SAFETY REPORT - 03-06-2021

3 June 2021

Information about the TGA's safety monitoring of COVID-19 vaccines.

ZOSTAVAX VACCINE

2 June 2021

Safety measures to address risk of infection with the vaccine virus COVID-19 VACCINE WEEKLY SAFETY REPORT - 27-05-2021

27 May 2021

Information about the TGA's safety monitoring of COVID-19 vaccines. COVID-19 VACCINE WEEKLY SAFETY REPORT - 20-05-2021

20 May 2021

Information about the TGA's safety monitoring of COVID-19 vaccines More safety information »

NEWS

V P & ASSOCIATES PTY LTD FINED $26,640 FOR ALLEGED UNLAWFUL ADVERTISING OF LIQUIM IN RELATION TO SARS-COV-2 CORONAVIRUS

3 June 2021

V P & Associates Pty Ltd fined $26,640 for alleged unlawful advertising of Liquim in relation to SARS-CoV-2 coronavirus DENTIST FINED $5,328 FOR ALLEGED UNLAWFUL IMPORTATION OF INJECTABLES

3 June 2021

Dentist fined $5,328 for alleged unlawful importation of cosmetic

injectables

QUEENSLAND MAN FINED $7,992 FOR ALLEGED UNLAWFUL IMPORTATION OF NOOTROPIC ‘SMART DRUGS’

3 June 2021

Queensland man fined $7,992 for alleged unlawful importation of nootropic ‘smart drugs’ CHANGES TO THE MEDICINE SHORTAGE REPORTING SYSTEM

2 June 2021

We are improving the Medicine Shortages IT System.

More news »

I WANT TO …

* Report a problem

* Ask a question

* Login to TGA Business Services * Subscribe to TGA updates

POPULAR

* Access to medicinal cannabis products * For travellers & visitors

* Fees & charges

* Poisons Standard (SUSMP) * Employment & job vacancies * Regulatory compliance * New prescription medicine & biological registrations * Medicine shortages

* Forms

* Publications

SEARCH DATABASES

* Australian Register of Therapeutic Goods (ARTG) * Adverse events (DAEN)

* Recalls (SARA)

* Prescribing medicines in pregnancy * Consumer Medicines Information (CMI) * Product Information (PI)

* New/Updated PIs

* Australian Public Assessment Reports for prescription medicines

(AusPARs)

* Ingredients

* TGA laboratory testing results * Listed medicine compliance reviews * Indications for Listed Medicines

LATEST TWEETS

CONNECT

* Copyright

* Privacy

* Disclaimer

* Security

* Acronyms & glossary

* Sitemap

* A-Z guide

* Contact the TGA

* Freedom of Information

SITEMAP NAVIGATION

* Home

* Safety information * Report a problem or side effect

* Alerts

* Recalls

* Prescription opioids * Medicine shortages * Early warning system * Black Triangle Scheme * Safety information & education

* COVID-19 vaccines

* Consumers

* Report a problem or side effect * Travelling with medicines and medical devices * Buying medicines and medical devices online

* Can I import it?

* Medicines

* Medical devices

* Advertising hub

* Consumer information & education * Health professionals * Report a problem or side effect * Accessing unapproved products

* Advertising

* Medicines

* Medical devices

* Biologicals

* Safety information

* Other resources

* Health professional information & education

* Industry

* SME Assist

* Regulation basics

* Advertising therapeutic goods * Prescription medicines * Over-the-counter medicines * Complementary medicines

* Sunscreens

* Medical devices & IVDs

* Biologicals

* Blood and blood components * Other therapeutic goods * Manufacturing therapeutic goods * Scheduling of medicines & poisons

* About the TGA

* TGA basics

* Contact the TGA

* Educational materials * Compliance and enforcement hub * Regulatory decisions & notices

* Committees

* Employment & job vacancies

* Fees and payments

* TGA Business Services

* International

* TGA Internet site archive

* News room

* News & public notices * Consultations & reviews * Events, training & presentations

* Blog

* www.australia.gov.au(link is external) * www.health.gov.au(link is external) * www.odc.gov.au(link is external) The Therapeutic Goods Administration is part of the Health Products

Regulation Group

Top of page